MX2017005788A - Vacunas terapeuticas contra el vph16. - Google Patents
Vacunas terapeuticas contra el vph16.Info
- Publication number
- MX2017005788A MX2017005788A MX2017005788A MX2017005788A MX2017005788A MX 2017005788 A MX2017005788 A MX 2017005788A MX 2017005788 A MX2017005788 A MX 2017005788A MX 2017005788 A MX2017005788 A MX 2017005788A MX 2017005788 A MX2017005788 A MX 2017005788A
- Authority
- MX
- Mexico
- Prior art keywords
- hpv
- protein
- nucleic acid
- provides
- polypeptides
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241000701806 Human papillomavirus Species 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 101000622322 Human papillomavirus type 16 Regulatory protein E2 Proteins 0.000 abstract 1
- 101710125507 Integrase/recombinase Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000027450 oncoproteins Human genes 0.000 abstract 1
- 108091008819 oncoproteins Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229940021747 therapeutic vaccine Drugs 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Otolaryngology (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
Abstract
La invención proporciona construcciones de ácidos nucleicos diseñadores y polipéptidos que pueden utilizarse como vacunas terapéuticas contra VPH16. Estos polipéptidos comprenden esencialmente todos los epítopos de células T posibles de oncoproteínas E6 y E7 del VPH 16, pero, no obstante, tienen una actividad transformante fuertemente reducida (en comparación con E6 y E7 wt) hasta no detectable, que comprenden fragmentos de las proteínas E6 y E7 que han sido re-ordenadas, conteniendo al mismo tiempo un número minimizado de neo-epítopos indeseados. La invención proporciona una molécula de ácido nucleico que codifica un polipéptido que comprende una secuencia como la recogida en la SEQ ID NO: 1. En determinadas realizaciones, el polipéptido codificado comprende, además, al menos un epítopo de una proteína E2 del virus del papiloma humano (VPH), por ejemplo una proteína E2 de VPH 16.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14191660 | 2014-11-04 | ||
PCT/EP2015/075516 WO2016071306A1 (en) | 2014-11-04 | 2015-11-03 | Therapeutic hpv16 vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005788A true MX2017005788A (es) | 2017-08-02 |
Family
ID=52020908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005788A MX2017005788A (es) | 2014-11-04 | 2015-11-03 | Vacunas terapeuticas contra el vph16. |
Country Status (33)
Country | Link |
---|---|
US (4) | US9701721B2 (es) |
EP (2) | EP3215187B1 (es) |
JP (2) | JP6325751B2 (es) |
KR (1) | KR20170083562A (es) |
CN (1) | CN107075521B (es) |
AR (1) | AR102527A1 (es) |
AU (2) | AU2015341926B2 (es) |
BR (1) | BR112017009177A2 (es) |
CA (1) | CA2965562C (es) |
CL (1) | CL2017001089A1 (es) |
CO (1) | CO2017004838A2 (es) |
CY (1) | CY1121377T1 (es) |
DK (1) | DK3215187T3 (es) |
EA (1) | EA035461B1 (es) |
ES (1) | ES2697903T3 (es) |
HR (1) | HRP20181895T1 (es) |
HU (1) | HUE040440T2 (es) |
IL (1) | IL251895B (es) |
LT (1) | LT3215187T (es) |
MA (2) | MA46378A (es) |
MD (1) | MD3215187T2 (es) |
MX (1) | MX2017005788A (es) |
MY (1) | MY181175A (es) |
NZ (1) | NZ730802A (es) |
PL (1) | PL3215187T3 (es) |
PT (1) | PT3215187T (es) |
RS (1) | RS58080B1 (es) |
SA (1) | SA517381457B1 (es) |
SG (1) | SG11201702997YA (es) |
SI (1) | SI3215187T1 (es) |
TW (2) | TWI731654B (es) |
WO (1) | WO2016071306A1 (es) |
ZA (1) | ZA201703055B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107075521B (zh) | 2014-11-04 | 2021-06-08 | 扬森疫苗与预防公司 | 治疗性hpv16疫苗 |
EA037295B1 (ru) | 2015-08-20 | 2021-03-05 | Янссен Вэксинс Энд Превеншн Б.В. | Терапевтические вакцины против hpv18 |
AU2017259259B2 (en) * | 2016-05-02 | 2020-11-19 | Bavarian Nordic A/S | Therapeutic HPV vaccine combinations |
CN106632694B (zh) * | 2017-01-24 | 2021-02-12 | 南京益康生物医药有限公司 | 一种重组蛋白及药物组合物与应用 |
EA202090628A1 (ru) * | 2017-09-23 | 2020-11-16 | Бёрингер Ингельхайм Ветмедика Гмбх | Система экспрессии paramyxoviridae |
US20200399348A1 (en) * | 2018-02-20 | 2020-12-24 | Emory University | HPV Proteins, Antibodies, and Uses in Managing Abnormal Epithelial Cell Growth |
JP2021517895A (ja) * | 2018-03-12 | 2021-07-29 | スクイーズ バイオテクノロジーズ カンパニー | Hpv関連疾患を処置するための方法 |
BR112021000274A2 (pt) * | 2018-07-20 | 2021-04-06 | Janssen Vaccines & Prevention B.V. | Vetor adenoviral recombinante expressando antígeno de zika com produtividade melhorada |
CN108939064B (zh) * | 2018-08-06 | 2021-12-10 | 南京颂悦生物科技有限公司 | 基于重组减毒绵羊李斯特菌的宫颈癌治疗性疫苗 |
CN108992665B (zh) * | 2018-08-06 | 2021-11-19 | 南京颂悦生物科技有限公司 | 基于重组减毒单增李斯特菌的宫颈癌治疗性疫苗 |
JP2022523564A (ja) | 2019-03-04 | 2022-04-25 | アイオーカレンツ, インコーポレイテッド | 機械学習を使用するデータ圧縮および通信 |
AU2020350137A1 (en) | 2019-09-20 | 2022-04-28 | Merck Patent Gmbh | Combination of a poxvirus encoding HPV polypeptides and IL-2 with an anti-PD-L1 antibody |
WO2021202949A2 (en) * | 2020-04-02 | 2021-10-07 | Inovio Pharmaceuticals, Inc. | Compositions and methods for treating vulvar dysplasia |
JP2023521194A (ja) | 2020-04-13 | 2023-05-23 | ヤンセン バイオテツク,インコーポレーテツド | Psma及びsteap1ワクチン並びにそれらの使用 |
AU2021270777A1 (en) * | 2020-05-12 | 2022-11-10 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
KR20230125200A (ko) | 2020-11-24 | 2023-08-29 | 마 무초우 조 | 인간 유두종 바이러스에 대한 dna 백신 및 이를 사용하는 방법 |
AU2022371672A1 (en) * | 2021-10-22 | 2024-05-16 | Inovio Pharmaceuticals, Inc. | Compositions and methods for treating anal high-grade squamous intraepithelial lesion (hsil) |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
DE69535178T2 (de) | 1994-06-10 | 2006-12-14 | Genvec, Inc. | Adenoviren-vektor systeme und zelllinien |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
ES2333425T5 (es) | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US5972650A (en) | 1997-06-26 | 1999-10-26 | Brigham And Women's Hospital | Tetracycline repressor regulated mammalian cell transcription and viral replication switch |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
EP1816205B1 (en) | 1999-05-17 | 2011-08-10 | Crucell Holland B.V. | Recombinant Adenovirus based on serotype 48 (Ad48). |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
JP2003509035A (ja) * | 1999-09-16 | 2003-03-11 | ザイコス インク. | ポリエピトープポリペプチドをコードする核酸 |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
JP2004510714A (ja) | 2000-10-04 | 2004-04-08 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア | フラビウイルス及びペスチウイルス由来のキャプシド蛋白質を使用する組成物及び方法 |
EE05680B1 (et) | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin |
AU2002257420A1 (en) | 2001-05-01 | 2002-11-11 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
SI1497438T1 (sl) | 2002-04-25 | 2010-03-31 | Crucell Holland Bv | Sredstva in postopki za pripravo adenovirusnih vektorjev |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
US20070014810A1 (en) * | 2003-12-31 | 2007-01-18 | Denise Baker | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
AU2005214090B2 (en) | 2004-02-23 | 2008-09-11 | Crucell Holland B.V. | Virus purification methods |
BRPI0517380A (pt) | 2004-11-08 | 2008-10-07 | Chromagenics Bv | molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse |
WO2007073513A2 (en) | 2005-11-10 | 2007-06-28 | Genvec, Inc. | Method for propagating adenoviral vectors encoding inhibitory gene products |
BRPI0708344B8 (pt) | 2006-02-28 | 2021-05-25 | Vaxart Inc | vetores adenovirais quiméricos e composição imunogênica |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
CN101617052A (zh) * | 2007-01-30 | 2009-12-30 | 特兰斯吉恩股份有限公司 | 用于免疫的乳头瘤病毒e2多肽 |
DE102008010954A1 (de) * | 2008-02-25 | 2009-08-27 | Cichon, Günter, Prof.Dr. | DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen |
ES2532015T3 (es) | 2008-11-03 | 2015-03-23 | Crucell Holland B.V. | Método para la producción de vectores adenovíricos |
GB0823497D0 (en) | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
WO2011098592A1 (en) | 2010-02-15 | 2011-08-18 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
CN103180343B (zh) * | 2010-08-13 | 2016-01-20 | 株式会社吉耐森 | 用于预防或治疗宫颈癌的、包含人乳头瘤病毒变形体及免疫增强剂的组合物 |
EP2780034A1 (en) | 2011-11-14 | 2014-09-24 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
EP2601968A1 (en) | 2011-12-06 | 2013-06-12 | Deutsches Krebsforschungszentrum | HPV derived polynucleic acids for therapy |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
SG10201901735XA (en) | 2014-09-03 | 2019-03-28 | Bavarian Nordic As | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
CN107075521B (zh) | 2014-11-04 | 2021-06-08 | 扬森疫苗与预防公司 | 治疗性hpv16疫苗 |
EA037295B1 (ru) * | 2015-08-20 | 2021-03-05 | Янссен Вэксинс Энд Превеншн Б.В. | Терапевтические вакцины против hpv18 |
AU2017259259B2 (en) * | 2016-05-02 | 2020-11-19 | Bavarian Nordic A/S | Therapeutic HPV vaccine combinations |
-
2015
- 2015-11-03 CN CN201580060062.4A patent/CN107075521B/zh active Active
- 2015-11-03 MA MA046378A patent/MA46378A/fr unknown
- 2015-11-03 PT PT15791556T patent/PT3215187T/pt unknown
- 2015-11-03 KR KR1020177014129A patent/KR20170083562A/ko active IP Right Grant
- 2015-11-03 SI SI201530481T patent/SI3215187T1/sl unknown
- 2015-11-03 CA CA2965562A patent/CA2965562C/en active Active
- 2015-11-03 EP EP15791556.2A patent/EP3215187B1/en active Active
- 2015-11-03 AU AU2015341926A patent/AU2015341926B2/en active Active
- 2015-11-03 HU HUE15791556A patent/HUE040440T2/hu unknown
- 2015-11-03 SG SG11201702997YA patent/SG11201702997YA/en unknown
- 2015-11-03 ES ES15791556T patent/ES2697903T3/es active Active
- 2015-11-03 MX MX2017005788A patent/MX2017005788A/es unknown
- 2015-11-03 JP JP2017523902A patent/JP6325751B2/ja active Active
- 2015-11-03 EA EA201790976A patent/EA035461B1/ru not_active IP Right Cessation
- 2015-11-03 RS RS20181369A patent/RS58080B1/sr unknown
- 2015-11-03 BR BR112017009177-1A patent/BR112017009177A2/pt active Search and Examination
- 2015-11-03 MA MA40902A patent/MA40902B1/fr unknown
- 2015-11-03 WO PCT/EP2015/075516 patent/WO2016071306A1/en active Application Filing
- 2015-11-03 EP EP18182588.6A patent/EP3421046A1/en active Pending
- 2015-11-03 DK DK15791556.2T patent/DK3215187T3/en active
- 2015-11-03 MD MDE20170071T patent/MD3215187T2/ro not_active IP Right Cessation
- 2015-11-03 PL PL15791556T patent/PL3215187T3/pl unknown
- 2015-11-03 LT LTEP15791556.2T patent/LT3215187T/lt unknown
- 2015-11-03 NZ NZ730802A patent/NZ730802A/en not_active IP Right Cessation
- 2015-11-03 MY MYPI2017701524A patent/MY181175A/en unknown
- 2015-11-04 AR ARP150103569A patent/AR102527A1/es unknown
- 2015-11-04 US US14/932,789 patent/US9701721B2/en active Active
- 2015-11-04 TW TW109113009A patent/TWI731654B/zh not_active IP Right Cessation
- 2015-11-04 TW TW104136379A patent/TWI694147B/zh not_active IP Right Cessation
-
2017
- 2017-04-25 IL IL251895A patent/IL251895B/en active IP Right Grant
- 2017-05-02 CL CL2017001089A patent/CL2017001089A1/es unknown
- 2017-05-03 SA SA517381457A patent/SA517381457B1/ar unknown
- 2017-05-03 ZA ZA201703055A patent/ZA201703055B/en unknown
- 2017-05-15 CO CONC2017/0004838A patent/CO2017004838A2/es unknown
- 2017-05-22 US US15/601,278 patent/US10071151B2/en active Active
-
2018
- 2018-04-12 JP JP2018076758A patent/JP6606571B2/ja active Active
- 2018-08-08 US US16/058,411 patent/US10555996B2/en active Active
- 2018-11-14 HR HRP20181895TT patent/HRP20181895T1/hr unknown
- 2018-11-15 CY CY20181101210T patent/CY1121377T1/el unknown
- 2018-12-21 AU AU2018282463A patent/AU2018282463B2/en active Active
-
2020
- 2020-01-29 US US16/775,709 patent/US11040096B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ730802A (en) | Therapeutic hpv16 vaccines | |
SA518390954B1 (ar) | لقاحات علاجية لفيروس الورم الحليمي البشري 18 | |
AU2019283892A1 (en) | Anti-human papillomavirus 16 E7 T cell receptors | |
MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
CR20200392A (es) | Anticuerpos anti-cd73 y métodos de uso de los mismos | |
PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
MX2023002858A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
MY172997A (en) | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides | |
PH12017501115A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use | |
NZ725079A (en) | Transgene genetic tags and methods of use | |
MX2023007211A (es) | Anticuerpos antimiostatina y metodos de uso. | |
WO2016116905A9 (en) | Cmv antigens and uses thereof | |
EP2589604A4 (en) | SHORTEN L1 PROTEIN OF THE TYPE 52 HUMAN PAPILLOMA VIRUS | |
CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
MX2019002178A (es) | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). | |
MY197457A (en) | Chimeric papillomavirus l1 protein | |
MX2019007924A (es) | Vacunas contra la influenza. | |
MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
WO2013138259A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
PH12018501532A1 (en) | Cancer vaccines | |
MX2009011851A (es) | Plasmidos de dna que tienen expresion y estabilidad mejoradas. | |
EA201692440A1 (ru) | Пролин-специфичная эндопротеаза и ее применение |